NO20054405L - Kjemokinreseptor-binende heterosykel - Google Patents

Kjemokinreseptor-binende heterosykel

Info

Publication number
NO20054405L
NO20054405L NO20054405A NO20054405A NO20054405L NO 20054405 L NO20054405 L NO 20054405L NO 20054405 A NO20054405 A NO 20054405A NO 20054405 A NO20054405 A NO 20054405A NO 20054405 L NO20054405 L NO 20054405L
Authority
NO
Norway
Prior art keywords
heterocycle
binding
chemokine receptor
compounds
useful
Prior art date
Application number
NO20054405A
Other languages
English (en)
Other versions
NO20054405D0 (no
Inventor
Dominique Schols
Gary J Bridger
Al Kaller
Curtis Harwig
Ernest J Mceachern
Krystyna A Skupinska
Renato T Skerlj
Yongbao Zhu
Gang Chen
Markus Metz
Ian Baird
Original Assignee
Anormed Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Anormed Inc filed Critical Anormed Inc
Publication of NO20054405D0 publication Critical patent/NO20054405D0/no
Publication of NO20054405L publication Critical patent/NO20054405L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Oncology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Virology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Communicable Diseases (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Neurology (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Forbindelser som interagerer med CXCR4-reseptoren, er beskrevet. Forbindelsene er anvendelige ved behandling av for eksempel HIV-infeksjon og inflammatoriske tilstander så som reumatoid artritt, samt astma eller kreft, og er anvendelige ved fremgangsmåter for forhøyning av progenitor- og stamcelletelleverdier, samt ved fremgangsmåter for forhøyning av telleverdier for hvite blodlegemer.
NO20054405A 2003-04-22 2005-09-22 Kjemokinreseptor-binende heterosykel NO20054405L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US46485803P 2003-04-22 2003-04-22
US50523003P 2003-09-22 2003-09-22
PCT/US2004/012627 WO2004093817A2 (en) 2003-04-22 2004-04-22 Chemokine receptor binding heterocyclic compounds with enhanced efficacy

Publications (2)

Publication Number Publication Date
NO20054405D0 NO20054405D0 (no) 2005-09-22
NO20054405L true NO20054405L (no) 2006-01-19

Family

ID=33313500

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20054405A NO20054405L (no) 2003-04-22 2005-09-22 Kjemokinreseptor-binende heterosykel

Country Status (17)

Country Link
US (2) US7550484B2 (no)
EP (2) EP1615633B1 (no)
JP (1) JP4778420B2 (no)
KR (1) KR20050115455A (no)
CN (1) CN101941964A (no)
AU (1) AU2004232361A1 (no)
BR (1) BRPI0409655B8 (no)
CA (1) CA2517077C (no)
ES (1) ES2393188T3 (no)
HK (1) HK1089930A1 (no)
IL (1) IL170207A (no)
IN (1) IN266744B (no)
MX (1) MXPA05011353A (no)
NO (1) NO20054405L (no)
NZ (1) NZ542850A (no)
RU (1) RU2005136224A (no)
WO (1) WO2004093817A2 (no)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ542850A (en) * 2003-04-22 2007-12-21 Anormed Inc Chemokine receptor binding heterocyclic compounds with enhanced efficacy
US7501518B2 (en) * 2003-04-22 2009-03-10 Genzyme Corporation Methods of making 2,6-diaryl piperidine derivatives
CN101094684A (zh) * 2004-08-13 2007-12-26 阿诺麦德股份有限公司 用趋化因子的组合活化祖细胞/干细胞
AU2006203826A1 (en) 2005-01-07 2006-07-13 Emory University CXCR4 antagonists for the treatment of HIV infection
CA2620306A1 (en) * 2005-08-25 2007-03-01 Repair Technologies, Inc. Devices, compositions and methods for the protection and repair of cells and tissues
JP5251127B2 (ja) 2005-10-28 2013-07-31 小野薬品工業株式会社 塩基性基を含有する化合物およびその用途
ES2407115T3 (es) 2005-11-18 2013-06-11 Ono Pharmaceutical Co., Ltd. Compuesto que contiene un grupo básico y uso del mismo
EP2041067A4 (en) 2006-07-11 2009-11-25 Univ Emory ANTAGONISTS OF CXCR4 COMPRISING DIAZINE AND TRIAZINE STRUCTURES FOR THE TREATMENT OF MEDICAL DISORDERS
CA2659463A1 (en) * 2006-08-02 2008-02-07 Genzyme Corporation Combination therapy
AU2007281677A1 (en) * 2006-08-07 2008-02-14 Genzyme Corporation Combination therapy
WO2009121063A2 (en) 2008-03-28 2009-10-01 Altiris Therapeutics Chemokine receptor modulators
CN103275071B (zh) * 2013-05-17 2015-04-15 山西大学 一种香豆素衍生物及其制备方法和用途
US20170105969A1 (en) * 2014-06-02 2017-04-20 Tobira Therapeutics, Inc. Cenicriviroc for the treatment of hiv-2 infection
ES2907489T3 (es) 2015-12-14 2022-04-25 X4 Pharmaceuticals Inc Métodos para el tratamiento del cáncer
CN109069486A (zh) 2015-12-14 2018-12-21 X4 制药有限公司 治疗癌症的方法
US11433136B2 (en) 2015-12-18 2022-09-06 The General Hospital Corporation Polyacetal polymers, conjugates, particles and uses thereof
JP7055380B2 (ja) 2015-12-22 2022-04-18 エックス４ ファーマシューティカルズ， インコーポレイテッド 免疫不全疾患を処置するための方法
WO2017177230A1 (en) 2016-04-08 2017-10-12 X4 Pharmaceuticals, Inc. Methods for treating cancer
WO2017223243A1 (en) 2016-06-21 2017-12-28 X4 Pharmaceuticals, Inc. Cxcr4 inhibitors and uses thereof
CN109562106B (zh) 2016-06-21 2023-03-21 X4 制药有限公司 Cxcr4抑制剂及其用途
CA3027495A1 (en) 2016-06-21 2017-12-28 X4 Pharmaceuticals, Inc. Cxcr4 inhibitors and uses thereof
WO2018106738A1 (en) 2016-12-05 2018-06-14 Massachusetts Institute Of Technology Brush-arm star polymers, conjugates and particles, and uses thereof
US10548889B1 (en) 2018-08-31 2020-02-04 X4 Pharmaceuticals, Inc. Compositions of CXCR4 inhibitors and methods of preparation and use
EP3990456A1 (en) * 2019-06-26 2022-05-04 X4 Pharmaceuticals, Inc. Cxcr4 inhibitors and uses thereof

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4810643A (en) 1985-08-23 1989-03-07 Kirin- Amgen Inc. Production of pluripotent granulocyte colony-stimulating factor
US6001826A (en) * 1989-12-21 1999-12-14 Anormed, Inc. Chemical compounds
US5021409A (en) 1989-12-21 1991-06-04 Johnson Matthey Plc Antiviral cyclic polyamines
GB9126677D0 (en) * 1991-12-16 1992-02-12 Johnson Matthey Plc Improvements in chemical compounds
US5235056A (en) * 1992-04-22 1993-08-10 Ciba-Geigy Corporation Substituted 1-hydroxy-2,6-diaryl-4-piperidone ketals and polymer compositions stabilized therewith
GB9400411D0 (en) 1994-01-11 1994-03-09 Johnson Matthey Plc Improvements in chemical compounds
GB9511357D0 (en) * 1995-06-06 1995-08-02 Johnson Matthey Plc Improved antiviral compounds
US6506770B1 (en) 1996-06-06 2003-01-14 Anormed, Inc. Antiviral compounds
US6365583B1 (en) * 1999-02-02 2002-04-02 Anormed, Inc. Methods to enhance white blood cell count
ES2265923T3 (es) 1999-03-24 2007-03-01 Anormed Inc. Compuestos heterociclicos que se unen a receptores de quimiocinas.
ES2240201T3 (es) * 1999-10-20 2005-10-16 Tanabe Seiyaku Co., Ltd. Inhibidores de la adhesion molecular mediada por la alfa-l beta-2.
ATE265219T1 (de) * 2000-05-09 2004-05-15 Univ British Columbia Verwendung von cxcr4 antagonisten zur behandlung von krebs und autoimmunkrankheiten
CA2419224A1 (en) 2000-09-15 2002-03-21 Anormed Inc. Chemokine receptor binding heterocyclic compounds
PT1317451E (pt) 2000-09-15 2006-12-29 Anormed Inc Compostos heterocíclicos que se ligam a receptores de quimioquinas
BR0113931A (pt) 2000-09-15 2004-01-13 Anormed Inc Compostos heterocìclicos ligantes receptores de quimiocinas
GB0030673D0 (en) * 2000-12-15 2001-01-31 Unilever Plc Ligand and complex for catalytically bleaching a substrate
JP2002284779A (ja) * 2001-01-18 2002-10-03 Sankyo Co Ltd ヘテロアリール置換ピロール誘導体を含有する医薬
GB0107228D0 (en) 2001-03-22 2001-05-16 Astrazeneca Ab Chemical compounds
US7491544B2 (en) * 2002-05-20 2009-02-17 New York University Chiral piperidine and quinucledine ligands
NZ542850A (en) * 2003-04-22 2007-12-21 Anormed Inc Chemokine receptor binding heterocyclic compounds with enhanced efficacy
US7498346B2 (en) 2003-12-11 2009-03-03 Genzyme Corporation Chemokine receptor binding compounds
US10468384B2 (en) 2017-09-15 2019-11-05 STATS ChipPAC Pte. Ltd. Semiconductor device and method of forming embedded die substrate, and system-in-package modules with the same

Also Published As

Publication number Publication date
EP1615633A4 (en) 2008-07-09
BRPI0409655B8 (pt) 2021-05-25
CA2517077A1 (en) 2004-11-04
US20050059702A1 (en) 2005-03-17
BRPI0409655B1 (pt) 2019-12-03
KR20050115455A (ko) 2005-12-07
WO2004093817A2 (en) 2004-11-04
NO20054405D0 (no) 2005-09-22
CA2517077C (en) 2013-03-12
WO2004093817A3 (en) 2005-04-28
EP1615633B1 (en) 2012-08-15
JP4778420B2 (ja) 2011-09-21
CN101941964A (zh) 2011-01-12
ES2393188T3 (es) 2012-12-19
IN266744B (no) 2015-05-29
MXPA05011353A (es) 2005-11-28
RU2005136224A (ru) 2006-06-10
BRPI0409655A (pt) 2006-04-18
EP2374804A1 (en) 2011-10-12
EP1615633A2 (en) 2006-01-18
HK1089930A1 (en) 2006-12-15
US7550484B2 (en) 2009-06-23
IL170207A (en) 2011-06-30
JP2006524700A (ja) 2006-11-02
US20090281308A1 (en) 2009-11-12
AU2004232361A1 (en) 2004-11-04
NZ542850A (en) 2007-12-21

Similar Documents

Publication Publication Date Title
NO20054405L (no) Kjemokinreseptor-binende heterosykel
DK1356052T3 (da) Produktion af hele antistoffer i prokaryotiske celler
UA90460C2 (ru) Фармацевтический препарат, который включает антитело против рецептора egf
BR112012015576A2 (pt) "cerâmica de vidro de dissilicato de lítio, método para sua fabricação e seu uso"
NO20080913L (no) HIV-revers-transriptaseinhibitorer
NO20083358L (no) Piperasinyl derivater som modulatorer for kjemokine reseptor aktivitet
NO20074943L (no) Roflumilast for behandlingen av diabetes mellitus
NO20065084L (no) Interferon-alfa polypeptider og konjugater
NO20064976L (no) Azanidoler som er nyttige som inhibitorer av rock og andre proteinkinaser
NO20070782L (no) Tetrapeptidanaloger.
BR0211442A (pt) Cepas de bifidobacterium probióticas
DE602005015110D1 (de) 4,6-disubstitutierte pyrimidine und deren verwendung als proteinkinase-hemmer
DE60042828D1 (de) Nicotinrezeptoragonisten in stammzellen und vorlaüferzellinduktion
NO20073765L (no) Forbindelser for behandling av flaviviridae
NO20065151L (no) Piperazinylpiperidinderivater som cytokin reseptor antagonister
DK2132221T3 (da) Template-fikserede peptidomimetika
DK1841765T3 (da) Imidazo[4,5-C]pyridinforbindelse og fremgangsmåde til antiviral behandling
BR112021022380A2 (pt) Inibidores de jak
CL2008003659A1 (es) Compuestos derivados de 6-(4-bencilpiperazin-1-il)pirimidin-4-ona, moduladores de la enzima estearoil-coa-desaturasa 1; procedimiento de preparacion; composicin farmaceutica; y uso en el tratamiento y profilaxis de la obesidad.
DK1411971T3 (da) Anvendelse af lang gentraxin PTX3 til behandling af kvindelig sterilitet
NO20082838L (no) 9-klor-15-deoksyprostaglandinderivater, fremgangsmate for fremstilling av disse, og anvendelse som medikamenter
NO20014890D0 (no) Fremgangsmåte for behandling av schizofreni
DK1853581T3 (da) 2-Sulfinyl- og 2-sulfonyl-substituerede imidazolderivater og deres anvendelse som cytokininhibitorer
WO2004094465A3 (en) Synthetic molecules that mimic chemokines
DE60325838D1 (de) Imidazoquinolinamine als adjuvantien für hiv dna vakzine

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application